Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials-Reference-Cited by-同舟云学术

Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials

Published:2007-01 Issue:3-4 Volume:26 Page:197-222
ISSN:0883-0185
Container-title:International Reviews of Immunology
language:en
Short-container-title:International Reviews of Immunology

Author:

Chiriva-Internati Maurizio,Cobos Everardo,Kast W. Martin

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/08830180701365966

Reference119 articles.

1. Myeloma Facts & Statistics. www.leukemia-lymphoma.org. Surveillance, Epidemiology and End Results (SEER), Cancer Statistics Review 1975–2003, National Cancer Institute, 2006.

2. Multiple Myeloma

3. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells

4. Characterization of clonogenic multiple myeloma cells

5. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis;International Reviews of Immunology;2015-03-04

2. Immune alterations and immunotherapy prospects in head and neck cancer;Expert Opinion on Biological Therapy;2013-06-24

3. Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma;International Reviews of Immunology;2012-01-17

4. Cancer Testis Antigen, Ropporin, Is a Potential Target for Multiple Myeloma Immunotherapy;Journal of Immunotherapy;2011-07

5. Sperm Protein 17: Clinical Relevance of a Cancer/Testis Antigen, from Contraception to Cancer Immunotherapy, and Beyond;International Reviews of Immunology;2011-05-10